Side-by-side comparison of AI visibility scores, market position, and capabilities
Singapore at-home fertility applicator for natural conception avoiding costly IVF/IUI; YC S20 $5.3M Monk's Hill Ventures-backed revenue-generating 2024 in SG/UK/US competing with Mosie Baby and Natalist for consumer fertility health products.
Twoplus Fertility is a Singapore-based consumer fertility health company — backed by Y Combinator (S20) with $5.3 million raised including a $5.15 million seed round led by Monk's Hill Ventures in May 2022 — providing couples experiencing difficulty conceiving with at-home fertility products designed as non-invasive, affordable alternatives to clinical fertility treatments, starting with the Twoplus Sperm Guide applicator (an at-home cervical cap applicator that positions sperm closer to the cervix during natural conception attempts, increasing the probability of fertilization for couples with mild male factor infertility or unexplained subfertility). Founded in 2019 by Prusothman Raja and Benjamin Tee, Twoplus became revenue-generating in 2024 and distributes products in Singapore, the United Kingdom, and the United States.
Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.